{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:15:32Z","timestamp":1784024132523,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jagp.2022.09.008","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T04:12:04Z","timestamp":1663992724000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient"],"prefix":"10.1016","volume":"31","author":[{"given":"Ethan","family":"Wainblat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Weleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2022.09.008_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52793\/JSCR.2020.1(1)-05","article-title":"Restoration of GABAA receptor function after benzodiazepine use: a meta-analysis","volume":"1","author":"Warlick","year":"2020","journal-title":"J Stem Cell Res"},{"key":"10.1016\/j.jagp.2022.09.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-019-1009-0","article-title":"Phenibut (\u03b2-Phenyl-\u03b3-Aminobutyric Acid): an easily obtainable \u201cDietary Supplement\u201d with propensities for physical dependence and addiction","volume":"21","author":"Jouney","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jagp.2022.09.008_bib0003","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1527-3458.2001.tb00211.x","article-title":"Phenibut (\u03b2-phenyl-GABA): a tranquilizer and nootropic drug","volume":"7","author":"Lapin","year":"2001","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.jagp.2022.09.008_bib0004","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.15585\/mmwr.mm6935a5","article-title":"Notes from the field: phenibut exposures reported to poison centers - United States, 2009-2019","volume":"69","author":"Graves","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jagp.2022.09.008_bib0005","unstructured":"Therapeutic Good Aministration: 2.3 Phenibut- Scheduling medicines and poisons [Australian Government, Department of Health and Aged Care, Therapeutic Good Adminstration]. September 15, 2017. Available at: https:\/\/www.tga.gov.au\/resources\/publication\/scheduling-decisions-interim\/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-march-and-july-2017\/23-phenibut. Accessed May 31, 2022."},{"key":"10.1016\/j.jagp.2022.09.008_bib0006","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1093\/jat\/bkab099","article-title":"Phenibut, a GABAB agonist, detected in a fatality","volume":"46","author":"Arndt","year":"2021","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.jagp.2022.09.008_bib0007","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.ajem.2019.02.044","article-title":"Phenibut exposures and clinical effects reported to a regional poison center","volume":"37","author":"McCabe","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jagp.2022.09.008_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/a-1151-5017","article-title":"Safety and tolerability of the anxiolytic and nootropic drug phenibut: a systematic review of clinical trials and case reports","volume":"53","author":"Kupats","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jagp.2022.09.008_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/08959420.2010.485511","article-title":"The baby boomer effect: changing patterns of substance abuse among adults ages 55 and older","volume":"22","author":"Duncan","year":"2010","journal-title":"J Aging Soc Policy"},{"key":"10.1016\/j.jagp.2022.09.008_bib0011","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.maturitas.2013.05.007","article-title":"Optimizing sleep in older adults: treating insomnia","volume":"76","author":"Wennberg","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.jagp.2022.09.008_bib0012","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14740338.3.5.485","article-title":"Safety of benzodiazepines in the geriatric population","volume":"3","author":"Madhusoodanan","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jagp.2022.09.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-016-0727-9","article-title":"Benzodiazepine misuse in the elderly: risk factors, consequences, and management","volume":"18","author":"Airagnes","year":"2016","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jagp.2022.09.008_bib0014","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults","volume":"63","author":"Samuel","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jagp.2022.09.008_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/add.15095","article-title":"Benzodiazepines: the time for systematic change is now","volume":"116","author":"Schmitz","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.jagp.2022.09.008_bib0016","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1460458214556373","article-title":"A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders","volume":"22","author":"Abdolahi","year":"2016","journal-title":"Health Informatics J"},{"key":"10.1016\/j.jagp.2022.09.008_bib0017","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1089\/tmj.2019.0134","article-title":"A validation study of the remotely administered Montreal cognitive assessment tool in the elderly Japanese population","volume":"26","author":"Iiboshi","year":"2020","journal-title":"Telemed e-Health"},{"key":"10.1016\/j.jagp.2022.09.008_bib0018","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/1357633X19890788","article-title":"Comparing face-to-face and videoconference completion of the Montreal Cognitive Assessment (MoCA) in community-based survivors of stroke","volume":"27","author":"Chapman","year":"2021","journal-title":"J Telemed Telecare"},{"key":"10.1016\/j.jagp.2022.09.008_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12875-017-0699-9","article-title":"Factors associated with the use of dietary supplements and over-the-counter medications in Japanese elderly patients","volume":"19","author":"Masumoto","year":"2018","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.jagp.2022.09.008_bib0020","first-page":"125","article-title":"Acute phenibut withdrawal: a comprehensive literature review and illustrative case report","volume":"19","author":"Hardman","year":"2019","journal-title":"Bosn J basic Med Sci"},{"key":"10.1016\/j.jagp.2022.09.008_bib0021","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/JCP.0000000000001104","article-title":"Detoxification of a patient with comorbid dependence on phenibut and benzodiazepines by tapering with baclofen: case report","volume":"39","author":"Coenen","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jagp.2022.09.008_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0091415016685330","article-title":"Sedative-hypnotic use among older adults participating in anxiety research","volume":"85","author":"Conti","year":"2017","journal-title":"Int J Aging Hum Dev"},{"key":"10.1016\/j.jagp.2022.09.008_bib0023","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dar.12356","article-title":"Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity","volume":"35","author":"Owen","year":"2016","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.jagp.2022.09.008_bib0024","article-title":"Phenibut addiction in a patient with substance use disorder","volume":"11","author":"Zheng","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jagp.2022.09.008_bib0025","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.jagp.2022.09.008_bib0026","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/15563650.2021.1973020","article-title":"Quantity of phenibut in dietary supplements before and after FDA warnings","volume":"60","author":"Cohen","year":"2022","journal-title":"Clin Toxicol (Phila)"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748122005188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748122005188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:34:18Z","timestamp":1761021258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748122005188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1064748122005188"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2022.09.008","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2022.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. on behalf of American Association for Geriatric Psychiatry. All rights reserved.","name":"copyright","label":"Copyright"}]}}